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1. Introduction 
Kidney transplantation is a relatively young field within medicine which continues to 
experience rapid advances in several areas. The number of immunosuppressive medications 
available to prevent and treat immunologic rejection of the transplanted organ has increased 
significantly since the late 1990’s, however, there continues to be a great need for developing 
novel, less toxic medications. The fine balance between over- and under-
immunosuppression is difficult to achieve in many transplant recipients, particularly as 
candidacy for kidney transplantation has expanded to include the elderly, patients with HIV 
and/or Hepatitis C infection, and sensitized transplant candidates. The relationship between 
infection and rejection remains closely intertwined, and can be a vicious cycle, with 
reduction of immunosuppression to manage infection potentially triggering rejection, and 
increased immunosuppression in the setting of rejection potentially leading to infectious 
complications. This chapter will focus on post-transplant complications resulting from over-
immunosuppression, specifically infection and malignancy.  
2. Infection  
The occurrence of infection after transplantation is a significant determinant of transplant 
outcome [1]. The incidence of infections after solid-organ transplantation is dependent on 
several factors, including the degree of immunosuppression, the type of organ transplanted, 
technical or surgical complications, need for additional antirejection therapy, environmental 
exposures, and the time frame after transplantation. A comprehensive list of factors 
contributing the ‘net state of immune deficiency’ can be found in reference [2]. Most recent 
United States data shows that infectious complications cause 20.9% of kidney transplant 
recipient death with a functioning allograft [3]. Infection also accounts for a significant 
proportion of death-censored graft loss, accounting for 7.7% of graft losses in the U.S. 
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between 1990 and 2006 [4]. Using the leading cause of allograft loss, chronic rejection as a 
reference, risk factors for infection-related graft loss included prior acute rejection and 
utilization of any induction therapy. Older transplant recipients (> 65 years at transplant) 
had a higher risk of infection related graft loss (14.1%). In this series, the infections leading 
to graft loss were caused by infections associated with urological complications and 
polyomavirus associated nephropathy [4]. Other infections that directly contribute to death-
censored graft loss include pyelonephritis and acute kidney injury in the setting of 
sepsis/critical illness.  
The occurrence of infection after transplantation usually falls within 3 general time frames: 
the first month, the second through the sixth month, and more than 6 months after 
transplantation [2, 5, 6]. Infections that occur during the first month after transplantation are 
generally the same nosocomial infections seen in non-immunosuppressed patients after 
surgery. These infections include bacterial and candidal urinary tract infection (UTI), 
wound/surgical site infections, catheter-related infections, and pneumonia.  
The period from the second to sixth month after transplantation is the time during which 
opportunistic infections “classically” associated with transplantation occur [1] , although the 
patterns have changed thanks to the availability of antimicrobial prophylaxis against some 
infections [2]. The most common infections during this period include cytomegalovirus 
(CMV), Pneumocystis (carinii) jiroveci, Aspergillus species, Nocardia species, Toxoplasmosis, 
Listeria monocytogenes, and fungal infections. In addition, reactivation of immunomodulating 
viruses will begin to manifest a clinically significant effect. These viruses include Epstein 
Barr virus (EBV), CMV, hepatitis B virus (HBV), hepatitis C virus (HCV), human 
herpesvirus type 6 (HHV-6), and human immunodeficiency virus (HIV) [1, 6]. Multi-drug 
resistant (MDR) bacteria such as Klebsiella, Pseudomonas, Acinetobacter, Staphylococcus, and 
Enterococcus can also be problematic during this period [5, 7-9].  
More than 6 months after transplantation, most transplant recipients (80%) are doing well 
[6], and can be classified into one of three risk groups [5]: 
1. Patients who have done well and immunosuppression is being tapered 
2. Patients who have required increased immunosuppression exposure due to rejection 
3. Patients at risk for late progressive viral reactivation (polyomavirus, CMV, HBV, HCV, 
HPV) 
The most common infections seen during this period mimic those seen in the general 
community [6]. Such infections include influenza virus, UTIs, and pneumococcal 
pneumonia. Although opportunistic infections are rarely observed during this time period, 
reactivation of varicella zoster virus (VZV) or CMV can occur. In addition, transplant 
recipients who have had multiple rejection episodes requiring additional antirejection may 
be predisposed to opportunistic infections more commonly seen 2 to 6 months after 
transplantation. It is recommended that patients being treated for acute rejection be placed 
back on opportunistic infection prophylaxis [10]. Transplant recipients experiencing chronic 
infection due to HBV, HCV, CMV, EBV, or HIV, resulting in a greater degree of morbidity, 
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are subsequently at an increased risk for other infections [1, 6]. In patients who undergo 
repeat transplantation, the typical timetable of infections may be altered. Infections 
characteristic of 1 of the 3 conventional time periods may occur simultaneously and with an 
increased severity [11]. In addition, modern immunosuppressive agents, as well as 
availability of prophylaxis against some infections has led to an altered timeline for many 
patients.  
Although not addressed in this chapter due to space constraints, transplant centers should 
be aware of the newer emerging infectious diseases that may affect transplant recipients 
[12]. This is also a great concern due to increasing rates of transplant tourism, where patients 
travel to foreign countries to receive a transplant and may be exposed to infectious 
complications not typically seen in their home country, where they will receive their follow-
up care. In addition, transplant recipients travelling for leisure should consult with a travel 
medicine specialist when possible [13].  
2.1. Bacterial infection 
Some of the most prevalent microbial pathogens observed after organ transplantation are 
bacteria. The specific bacterial infections that occur after transplantation can be divided into 
4 categories [14]: 
 Infections due to surgical or technical complications, 
 Infections related to prolonged hospitalization (nosocomial infections), 
 Infections associated with the degree of immunosuppression (opportunistic infections), 
and 
 Infections occurring months after transplantation when the transplant recipient resumes 
normal activity (community-acquired infections). 
Although transplant recipients are susceptible to common bacterial pathogens observed in 
normal hosts, the immunosuppressed state of the recipient after transplantation predisposes 
the patient to bacterial pathogens not commonly observed in the normal host. These 
opportunist pathogens include Legionella species, Nocardia species, Rhodococcus species, L 
monocytogenes, and Mycobacteria species. Following transplantation, disruption of anatomic 
barriers is commonly associated with bacterial infections. For instance, the upper airway is 
normally colonized with bacteria, and the lower respiratory tract is normally sterile. 
Endotracheal intubation creates a conduit between the upper and lower respiratory tract, 
introducing bacteria to the lower respiratory tract and resulting in disease of the bronchial 
tubes or lung parenchyma. Indwelling urinary and vascular catheters may become 
colonized with nosocomial bacteria or cutaneous flora and introduce these pathogens into 
the urinary tract, transplant kidney, or bloodstream. 
2.1.1. Urinary tract infection 
The most common infections occurring after kidney transplantation are UTIs, which may 
include asymptmatic bacteriuria, cystitis, and/or pyelonephritis. The reported incidence of 
 Current Concepts in Kidney Transplantation 172 
UTI in kidney recipients is 7.3% to to 90% [15-18] with the variation likely due to differences 
in definitions of infection and prophylactic strategies. Predisposing factors include renal 
insufficiency, ischemic changes of the graft, decreased urine flow through the urinary 
epithelium, prolonged urinary catheterization, ureteral stenting, post-transplant diarrhea, 
and underlying medical conditions such as diabetes mellitus, female gender, urinary tract 
abnormalities, bladder dysfunction, and bladder outlet obstruction [17-20]. In pediatric 
kidney transplant recipients, age less than 5 at the time of transplant and lower urinary tract 
abnormalities may be risk factors for post-transplant UTI [21]. Studies analyzing whether 
the utilization of double-J ureteral stents during a kidney transplant procedure increases the 
risk of post-transplant UTI have produced conflicting results [22-24]. It has been suggested 
that a shorter duration (3 weeks versus 6 weeks) of ureteral stent placement may reduce the 
incidence of UTI [24].  
The most common pathogens implicated in UTIs include E. coli, Staphylococci, Enterococci, 
Enterobacter and Pseudomonas aeruginosa [20, 25]. Despite routine treatment of asymptomatic 
bacteriuria, patients still develop symptomatic cystitis and pyelonephritis, and recurrent 
asymptomatic bacteriuria has been shown to be an independent risk factor for transplant 
pyelonephritis [16]. Recurrent UTI can also contribute to inflammation and fibrosis of the 
allograft [16, 26]. Bloodstream infections, the majority (75%) of which were due to a urinary 
source (E. Coli in 50% of infections) have also been shown to lead to allograft failure (either 
directly or by causing death) and all-cause mortality [27]. It is recommended that all UTI’s in 
kidney transplant recipients be considered complicated, and thus short-term treatment 
regimens are not recommended [20].  
2.1.2. Clostridium difficile associated diarrhea and colitis 
Clostridium difficile associated diarrhea (CDAD) and C. difficile colitis are an increasingly 
important cause of morbidity and mortality after solid organ transplantation, with reported 
incidence of 0.5% to 16.0% of kidney transplant recipients [28-30]. CDAD tends to occur 
early in the post-transplant period, although later cases related to exposure to antibiotics or 
increased immunosuppression due to allograft rejection also occur. Transplant recipients are 
also at higher risk for fulminant C. difficile colitis as compared to the general population. 
CDAD is often difficult to eradicate completely, leading to recurrent infection, due to the 
fact that it is a spore forming bacterium.  
Risk factors for CDAD include older age, antimicrobial exposure, and rabbit anti-thymocyte 
globulin induction therapy [30, 31]. For patients developing fulminiant CDAD, risk factors 
identified include peak leukocyte count of 25,000/mm3 or greater and evidence of pancolitis 
on CT scan. For those developing fulminant CDAD, colectomy has been associated with 
improved patient and graft survival when compared to patients managed with medical 
therapy alone [30]. Medications that suppress gastric acid production, commonly used in 
transplant recipients, may also increase risk of CDAD [31].  
The most commonly utilized diagnostic test for CDAD is C. difficile toxin detection in the 
stool via ELISA [31]. Antimicrobial management of CDAD includes oral metronidazole (first 
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line for mild to moderate CDAD) or oral vancomycin (for severe CDAD), with intravenous 
(IV) metronidazole added in severe cases [31]. It is important to note that IV vancomycin 
does not penetrate the intestinal lumen, and is therefore ineffective for managment of 
CDAD. The removal or reduction in other antibiotics is an important adjunctive step. 
Surgery is often necessary in fulminant cases, in order to avoid colonic rupture. Other 
adjunctive therapies sometimes employed but with less supporting data include 
vancomycin enema, Lactobacillus probiotic supplementation, and intravenous immune 
globulin (IVIG) [5, 31]. An algorithm for management of patients with C. difficile infection 
can be found in reference [31].  
2.1.3. Tuberculosis 
Worldwide, the estimated incidence of tuberculosis (TB) (Mycobacterium tuberculosis) in 
kidney transplant recipients is 20 to 70 times that of the general population [32]. Treatment 
of active TB infection in transplant recipients is complicated due to drug interactions, 
antimicrobial resistance, and toxicity of the antimicrobials used for treatment of TB. 
Extrapulmonary involvement, atypical presentation, and limitations of the tuberculin skin 
test make diagnsois difficult. Although newer methods are available, which measure release 
of interferon  (such as Quantiferon Gold), more data is needed regarding utilization of 
these assays in kidney transplant candidates and recipients [33]. 
Identification of high risk patients (those living in endemic areas or those with prior 
infection or exposure) is essential in order to administer prophylaxis with isoniazid (INH). 
A meta analysis of INH prophylaxis in kidney transplant recipients found that the relative 
risk of TB infection was significantly reduced, while risk of toxicity (hepatitis) did not differ 
between patients that did or did not receive prophylaxis [33]. Current European [34] and 
U.S. [35] guidelines recommend 9 months of INH prophylaxis for those with latent TB 
infection, however, the optimal timing of prophylaxis is unclear, particularly for patients 
awaiting a deceased donor transplant. When treating transplant recipients with active 
tuberculosis, close monitoring of calcineurin inhibitor levels with concomitant dose increase 
is needed due to presence of rifampin or related drugs in the anti-tuberculosis regimen [35].  
2.1.4. Prophylaxis of bacterial infection 
Trimethoprim/sulfamethoxazole (TMP/SMX), traditionally used for prophylaxis against 
Pneumocystis jiroveci pneumonia, has proven efficacy in reducing the incidence of UTIs, as 
well as bacteremias after transplantation [36, 37], although resisitance to common urinary 
tract pathogens is increasingly common in more recent years [16, 38]. TMP/SMX is also 
effective in preventing infections by L monocytogenes, Nocardia species, and Toxoplasmosis 
gondii, leading to recommendations for its use in all patients without contraindication to its 
use [2]. Therapy should continue for at least 6 months after transplantation, although the 
duration varies from center to center. In sulfa-allergic patients, alternatives to TMP/SMX 
include atovaquone, pentamidine, and dapsone. For patients not on TMP/SMX, 
ciprofloxacin (x 3 to 6 months) has been recommeded as UTI prophylaxis [20]. 
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To prevent surgical wound and abdominal infections, the local perioperative antibacterial 
prophylaxis should be administered. The prophylactic antibiotic of choice should be 
determined by the resident flora of the transplanted, the prevalent bacterial flora identified 
in wound infections and the institutional antibiotic susceptibility pattern [39]. In kidney 
transplant recipients, the target pathogens include uropathogens and staphylococci; hence 
either a first-generation cephalosporin or ampicillin/sulbactam is an appropriate 
prophylactic agent. More recently, it has been suggested that due to the low incidence of 
surgical site infection observed in the absence of peri-operative antimicrobial prophylaxis, 
prophylaxis should only be used in higher risk patients (> 65 years of age and/or obese 
(defined as body mass index > 35)) in order to reduce resistance, adverse events, and cost 
[40]. Obesity, an established risk factor for wound complications, is often targeted prior to 
transplant. Interestingly, significant pre-transplant weight loss has also been identified as a 
risk factor for wound complications, attributed to body contour changes resulting in an 
unfavorable abdominal panniculus [41].  
2.1.5. Treatment of bacterial infection 
The antibiotic of choice for the treatment of infection after renal transplantation is largely 
dependent on the susceptibility of the bacteria identified in the urine, blood, or wound 
culture, and is very important due to increasing bacterial resisitance to commonly used 
antimicrobials. Fluoroquinolones, cephalosporins, or penicillins are commonly used to treat 
UTIs. For infections due to coagulase-negative staphylococci or ampicillin-resistant 
enterococci, vancomycin is utilized. Critically ill patients require intial broad spectrum 
antimicrobials, which should then be narrowed as culture results become available. 
Nephrotoxic agents (such as aminoglycosides) should be avoided whenever possible, 
relying on effective non-nephrotoxic alternatives instead.  
Treatment duration depends on the origin and severity of infection. Wound infections and 
most UTIs require treatment for 5 to 7days, whereas pyelonephritis usually requires 2 weeks 
of therapy or longer. Imaging to rule out obstruction or anatomic abnormalities should be 
considered in cases of recurrent UTIs. In addition, wound infections may require 
debridement with an adjunctive antibiotic regimen. Patients with neutropenic fever may 
receive granulocyte colony stimulating growth factors, which have been shown not to 
increase the risk of acute rejection [5]. Depending on the severity of the infection, reduction 
in immunosuppression, with close monitoring of graft function, may also play an important 
role in clearing the infection.  
2.2. Fungal infection 
Invasive fungal infections are a significant infectious complication among solid-organ 
transplant recipients and remain a major cause of morbidity and mortality. Among all solid-
organ transplant recipients, kidney transplantation is currently associated with the lowest 
rate of fungal infections, with a one-year cumulative incidence of 1.3% [46]. Candida, 
Aspergillus, and Cryptococcus are the most common fungal pathogens in solid-organ 
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transplantation [42]. The Transplant-Associated Infection Surveillance Network 
(TRANSNET) reports that leading invasive fungal infections are candidiasis (49%), 
Cryptococcus (15%), Aspergillosis (14%), and endemic mycoses (10%) [43]. In this report, 
Pneumocystis represented only 1% of invasive fungal infections, likely demonstrating the 
effectiveness of prophylactic strategies.  
Pneumocystis jiroveci pneumonia (PJP) usually occurs within the first 6 months after 
transplantation without prophylaxis. Risk factors for PJP include prior CMV infection, 
underlying pulmonary disease, allograft dysfunction, net state of immunosuppression, 
allograft rejection, and prolonged neutropenia [44, 45]. Recently, a nosocomial cluster of PJP 
was reported, spread via exposure in clinic waiting areas [44]. Universal prophylaxis against 
PJP is recommended for 6 to 12 months after transplant [45].  
The most common pathogen is the Candida species, mostly Candida albicans or less 
commonly, Candida glabrata, C. tropicalis, or C. parapsilosis [43, 46]. Identifying the species of 
Candida is important for choosing appropriate antifungal agents, and C. glabrata should be 
tested for antifungal susceptibility, especially in areas with known resistance or if the 
infection is not responding to the initial therapy [43]. The majority of these infections occur 
within the first 2 months after transplantation, and occur as candidemia, UTI, or peritonitis 
[43]. Asymptomatic candiduria is generally not treated unless the patient is neutropenic or 
will be undergoing a urologic procedure, while symptomatic candiduria is usually treated 
[43, 47]. Imaging of the transplant kidney to rule out abscess in the collecting system or 
presence of fungus ball(s) is also recommended [43, 47]. Fluconazole is the only azole to 
concentrate in the urine, and so has an important role in the treatment of Candida UTI’s.  
Infections due to endemic fungi typically occur in the mid to late posttransplantation period, 
although some do occur within 2 months of transplant. Endemic fungal infections are 
associated with pathogens like Histoplasma capsulatum, Blastomyces dermatitidis, and 
Coccidioides immitis. For detailed review of the various types of fungal infections in solid 
organ transplantation, the reader is referred to references [42, 45, 46, 48-51]. Although rare, 
donor-derived fungal infections are important to consider; recent guidelines outline 
occurrence and management of such infections [48]. 
2.2.1. Prevention and treatment of fungal infections 
Systemic prophylaxis of fungal infection is generally not required for kidney transplant 
recipients. Prevention of oral candidiasis is achieved through use of topical nystatin or 
clotrimazole. Multiple options are available for the treatment of invasive fungal infections in 
solid-organ transplantation, including amphotericin B (liposomal formulations preferred 
due to less nephrotoxicity), azole antifungals (fluconazole, itraconazole, voriconazole, 
posiconazole) and echinocandins (caspofunginm micafungin, anidulafungin). The optimal 
regimen should be based on antifungal susceptibility testing. Detailed review of these 
agents is beyond the scope of this chapter, however, a brief discussion of drug-drug 
interactions between antifungal agents and immunosuppressants is warranted, as well as 
mention of toxicities of concern in kidney transplant recipients (see Section 2.5).  
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2.3. Viral infection 
Many factors affect the development of viral infection after solid-organ transplantation. 
These factors include recipient and donor serostatus, recipient comorbidities (eg, diabetes 
mellitus), immunosuppression regimen, organ(s) transplanted, ischemia-reperfusion injury 
to graft, and community-acquired infection. Viral infection can be particularly devastating 
to transplant recipients because of the immunosuppressive properties of the viral pathogens 
themselves, which may increase the patients’ susceptibility to other opportunistic infection 
(particularly fungal infection), or posttransplant lymphoproliferative disease (PTLD). 
2.3.1. Cytomegalovirus 
Cytomegalovirus (CMV), a herpesvirus, is the most important viral infection in solid-organ 
transplantation because of its broad effects on immunocompromised patients [6]. Active 
infection produces not only signs and symptoms associated with the viral syndrome itself, 
but also has other widespread effects associated with cytokine-mediated inflammatory 
response and generation of cross-reactive T cells [52]. These effects may lead to allograft 
injury and/or acute rejection, systemic immunosuppression from the virus, and EBV-
associated PTLD [6]. Risk factors for CMV infection/disease include CMV donor-
positive/recipient-negative (D+/R-) serostatus pairs, recent treatment for acute rejection, 
recent completion of prophylactic antiviral therapy, and rabbit anti-thymocyte globulin 
induction therapy [53, 54]. In CMV D+/R- pairs, there may be an association between the use 
of CMV prophylaxis and improved graft survival and lower acute rejection rates [55].  
Clinical Manifestations 
Differentiation between CMV infection and CMV disease is important when assessing a 
patient for CMV. A patient with CMV infection has active viral replication in the blood or 
other body fluids, but does not necessarily experience systemic signs and symptoms such as 
malaise, fever, and pancytopenia. Patients with CMV disease, however, most commonly 
have a viral syndrome with fever or have invasive infection that has affected an organ 
system, such as colitis, hepatitis, or pneumonitis [56]. 
Diagnosis and Monitoring 
CMV serology of the donor and recipient are useful for estimating the recipient’s risk of 
CMV developing after transplantation, but is not useful for diagnosing CMV 
infection/disease because seroconversion often does not occur until after symptoms are 
resolved [10, 53, 57]. Rather, methods that quantify the extent of the CMV infection are 
necessary to make the diagnosis. Two common methods include CMV antigenemia (stain 
circulating neutrophils for CMV antigen) and CMV DNA polymerase chain reaction (PCR) 
(quantitative viral load) [58]. A major limitation of antigenemia is the need for sufficient 
quantities of neutrophils to perform the test, which is often not possible because of the 
neutropenia caused by the CMV virus itself. Therefore, the CMV viral load is a key 
diagnostic tool; trends in viral loads are more valuable than individual levels [57]. Viral load 
assays vary between laboratories, however, and assay standardization is needed. Another 
 
Complications of Kidney Transplantation: Effects of Over-Immunosuppression 177 
limitation includes the fact that peripheral viral load may be undetectable in patients with 
invasive CMV disease, particularly when the gastrointestinal tract and lungs are sites of 
infection. In these cases, biopsy of the infected tissue and/or bronchial alveolar lavage is 
often necessary to confirm diagnosis [57]. 
Prevention 
Several strategies have been used to prevent and treat CMV. Some centers routinely provide 
antiviral prophylaxis (called universal prophylaxis) to patients at risk for CMV (particularly 
D+/R- pairs), whereas others employ preemptive strategies, in which patients are routinely 
monitored and receive prophylaxis only if laboratory markers become positive. Each 
method has benefits and drawbacks. Benefits of universal prophylaxis include preventing 
both CMV and other herpes viruses and lack of need for intensive monitoring. Drawbacks 
include the risk of developing ganciclovir-resistant CMV (although a small risk), adverse 
effects of the medications, the fact that late CMV disease may occur despite early 
prophylaxis (delayed onset), and the fact that the disease may have atypical features. 
For preemptive strategies, benefits include decreasing the use of antivirals and their 
associated adverse effects and costs. However, the logistically demanding monitoring 
schedule, requirement for strict compliance to the costly surveillance methods, potential to 
develop CMV disease before detection, and development of drug resistance are 
disadvantages of preemptive strategies [57]. CMV-related morbidity is also a significant risk 
when adherence to monitoring guidelines is poor [59]. Drug resistance can occur if 
ganciclovir is used in a patient with active viral replication, owing to its poor oral 
bioavailability. A recent prospective randomized trial of pre-emptive therapy versus 
valganciclovir prophylaxis in CMV serostatus positive kidney transplant recipients found 
that both CMV infection and CMV disease were significantly higher in the pre-emptive 
group, in particular for D+/R+ patients [60]. The general consensus is that the highest risk 
patients (D+/R-) should receive universal prophylaxis [10, 61].  
With the introduction of valganciclovir, a prodrug of ganciclovir with superior oral 
bioavailability, interest has focused on use of this agent to prevent and treat CMV infection 
and disease. For outpatients, valganciclovir 900 mg per day or ganciclovir 1000 mg three 
times per day are commonly used to prevent CMV [10]. Pharmacokinetic studies show that 
oral valganciclovir administration at 450 mg (given once daily) gives exposure that is 
equivalent to the standard oral regimen of ganciclovir (1 g administered 3 times a day) [62]. 
The manufacturer-recommended dose of valganciclovir for CMV prophylaxis is 900 
mg/day, and this dose appears to be equivalent in efficacy to oral ganciclovir, with an 
increased incidence of neutropenia compared with ganciclovir [56]. In several studies, 
researchers have retrospectively evaluated the efficacy of low-dose valganciclovir (450 mg 
daily) as prophylaxis for CMV in kidney transplant recipients [63]. An analysis comparing 3 
months of standard ganciclovir versus low dose valganciclovir in the prophylaxis of CMV in 
129 kidney or pancreas transplant recipients revealed a 14% incidence of CMV disease at 1 
year after transplantation (10% noninvasive and 4% invasive) [63]. The incidence was 
similar between patients receiving ganciclovir and valganciclovir, and risk factors for 
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development of CMV disease included CMV D+/R- serostatus and use of thymoglobulin as 
part of immunosuppression regimen (incidence 25% in patients receiving thymoglobulin). 
The same investigators later reported outcomes in 37 kidney or pancreas recipients who 
received thymoglobulin induction and an extended course (6 months) of CMV prophylaxis 
with low-dose valganciclovir [64]. The incidence of CMV disease decreased in 
thymoglobulin-treated patients from 25% to 8% when prophylaxis was extended from 3 
months to 6 months.  
The duration of CMV prophylaxis also remains controversial; current recommendations 
suggest a minimum of 3 months of therapy [10]. Several studies have demonstrated a lower 
incidence of CMV disease after transplantation in patients receiving prophylaxis for 6 
months, particularly in patients at highest risk for developing CMV [53, 64-67]. From a 
pharmacoeconomic perspective, prolonged (200 days vs. 100 days) valganciclovir 
prophylaxis for high-risk patients (D+/R-) has been shown to be cost-effective [68]. 
Treatment 
Patients with CMV infection/disease should be treated with IV ganciclovir or oral 
valganciclovir; IV ganciclovir should be used in severe/life-threatening cases, and when 
gastrointestinal symptoms (such as diarrhea) may limit absorption of valganciclovir [10]. 
Ganciclovir (IV) is the gold standard for treatment due to the large body of experience with 
it and its lack of nephrotoxicity, which limits the use of other antiviral agents such as 
cidofovir and foscarnet. The treatment dose of 5 mg/kg IV every 12 hours must be adjusted 
for renal function; this adjustment should be done carefully, as subtherapeutic ganciclovir 
exposure in the setting of high CMV viral load may promote the development of resistance 
[57]. Because the bone marrow–suppressive effects of ganciclovir may further compound the 
neutropenia caused by the CMV virus itself, care should be exercised in adjusting the dose 
of ganciclovir to avoid these effects. Rather, use of white blood cell growth factors may be 
preferable in order to avoid the subtherapeutic ganciclovir exposure [57]. At a dose of 900 
mg, valganciclovir provides exposure similar to that of 5 mg/kg body weight of IV 
ganciclovir, and can also be administered twice per day for treatment of active CMV 
infection [10, 62]. Thus, the cost of treating active CMV infection could be substantially 
lowered by its potential to treat with oral valganciclovir in the outpatient setting, for mild to 
moderate cases in patients not experiencing significant gastrointestinal symptoms (ie. 
diarrhea) [10]. Another key component of managing patients with CMV disease includes 
careful reduction in immunosuppression, taking into consideration patient and organ-
specific factors. CMV immunoglobulin may also have an adjunctive role in treatment of 
severe CMV disease [10, 57]. 
Close monitoring of viral load is necessary to assess response to therapy; monitoring should 
begin 1 week after initiation of therapy and treatment should be continued until the viral 
load has been undetectable for 1 week [57]. The role of secondary prophylaxis after 
treatment is not clearly defined. When secondary prophylaxis is employed, viral load 
should be monitored for potential development of resistance and use of valganciclovir may 
be preferable owing to its superior bioavailability [57]. CMV disease recurs in approximately 
 
Complications of Kidney Transplantation: Effects of Over-Immunosuppression 179 
15% to 35% of patients. Recurrence is due to incomplete suppression of CMV rather than the 
development of resistance. Patients at higher risk for recurrence include D+/R- pairs, 
multisystem CMV disease, those who receive treatment for acute rejection, patients with 
high viral loads at the time of initial diagnosis of the infection, and those who had a 
detectable viral load at the end of therapy for the initial infection [57].  
Ganciclovir-resistant strains of CMV have developed in recent years, and are attributed to 
mutation of the UL97 +/- the UL54 gene(s), with the combined mutations leading to a high-
level of ganciclovir resistance [10, 69]. Patients at highest risk for developing ganciclovir-
resistant CMV include D+/R- pairs, as well as kidney-pancreas transplant recipients [57]. 
Utilization of pre-emptive strategies in D+/R- patients has been associated with 
development of GCV-resistance in more than 10% of patients [70]. Treatment of ganciclovir-
resistant strains includes high-dose IV GCV, combination therapy with ganciclovir plus 
foscarnet, and CMV hyperimmunoglobulin [10, 57]. Increasing the ganciclovir dose (up to 
10 mg/kg every 12 hours) with careful monitoring for toxic effects may also be useful in 
these patients [57]. An algorithm for management of ganciclovir resistance can be found in 
reference [10].  
2.3.2. Varicella zoster virus 
The adult seroprevalence rate for varicella zoster virus (VZV) in the United States is greater 
than 90%. Primary varicella infection is a risk for seronegative transplant recipients; adults 
are more likely to experience severe infection leading to complications such as hepatitis, 
pneumonitis, and encephalitis. In an analysis of herpes zoster (shingles) infection in the 
setting of modern immunosuppression, researchers evaluated 869 solid-organ transplants 
performed between 1994 and 1999, and the incidence of varicella zoster was 7.4% in kidney 
recipients. Herpes zoster infection occurred at a median of 9.0 months after transplantation 
and resulted in significant morbidity; 62.7% of cases were within 1 year of transplant. 
Independent risk factors for infection included induction therapy and antiviral therapy 
(other than >6 weeks of CMV prophylaxis with acyclovir or ganciclovir) [71].  
Clinical Manifestations 
Cutaneous scarring, defined as skin disfigurement (scarring or hypopigmentation), occurred 
in 18.7% of patients with herpes zoster, usually following a dermatomal pattern. 
Postherpetic neuralgia, defined as pain persisting more than 30 days after rash 
development, occurred in 42.7% of patients [71]. More serious manifestations of VZV 
infection may include pneumonitis, hepatitis, or encephalitis. This is especially true in 
primary infections, where morbidity and mortality may be high. 
Diagnosis and Monitoring 
Diagnosis of VZV infection typically involves clinical examination of skin lesions. Viral 
cultures, direct fluorescent antibody assays, or PCR testing may be used to confirm 
diagnosis when necessary [72]. 
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Prevention 
CMV prophylaxis with ganciclovir will most likely prevent VZV, although acyclovir is 
effective for those patients not receiving ganciclovir [72]. Patients who are VZV seronegative 
before transplantation should be vaccinated against varicella whenever possible, although 
pre-transplant administration of the herpes zoster vaccine, Zostavax is not recommended at 
this time due to a higher live-virus content [72]. The varicella vaccine should not be 
administered to patients receiving immunosuppressants, because the varicella vaccine is a 
live, attenuated vaccine that may cause infection in immunocompromised patients. After 
transplantation, seronegative patients exposed to VZV should receive postexposure 
prophylaxis, although this is not guaranteed to prevent infection. Postexposure prophylaxis 
consists of varicella zoster immunoglobulin if the patient arrives for treatment within 96 
hours of initial exposure (preferred), or antiviral therapy if that 96-hour window has passed. 
However, the immunoglobulin preparation is no longer widely available to transplant 
centers, so IVIG may be utilized [72]. Although some centers have reported administration 
of the varicella vaccine after liver transplantation with minimal adverse effects [73], others 
have reported development of infection [74]. Therefore, this practice remains controversial 
and is not supported by existing guidelines [72]. 
Treatment 
Patients with active, serious VZV infection should be treated with IV acyclovir, whereas less 
serious infections may be treated with oral acyclovir, valacyclovir, or famciclovir. In rare 
cases of acyclovir resistance, foscarnet may be used [72]. 
2.3.3. Herpes simplex virus 1 and 2 
Adult seroprevalence rates for herpes simplex virus 1 and 2 in the U.S. are 62% and 22%, 
respectively. Most infections after transplantation are due to reactivation of latent virus. 
Clinical Manifestations 
Infection with herpes simplex virus generally is manifested by orolabial lesions or 
genital/perianal lesions, although more serious systemic infection can result in esophagitis, 
hepatitis, or pneumonitis. 
Diagnosis and Monitoring 
Diagnosis of infection with herpes simplex virus 1 or 2 typically involves clinical 
examination of skin lesions. Culture of scrapings/tissue from lesions may be necessary to 
confirm diagnosis in some cases, and PCR assays are increasingly being used [75]. 
Prevention and Treatment 
CMV prophylaxis with ganciclovir will most likely prevent HSV; acyclovir is effective for 
those patients not receiving ganciclovir [59]. HSV infections are usually treated with oral 
acyclovir, valacyclovir, or famciclovir [75]. In more serious infections, IV acyclovir may be 
employed, although alternative therapy such as foscarnet may be required in cases of 
acyclovir resistance [75]. 
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2.3.4. Human herpesvirus 6, 7 and 8 
Human herpesvirus (HHV) 6 and 7 are viral pathogens that can cause significant morbidity 
and mortality in transplant recipients. Although HHV 6 infection has been most commonly 
reported among stem cell transplant recipients, cases have also been reported in solid-organ 
transplant recipients [76-78]. As with CMV, HHV 6 and 7 appear to have 
immunomodulatory effects and may predispose patients to secondary infection. Indeed, the 
mortality associated with HHV 6 appears to be related primarily to the development of 
secondary fungal infection [77, 78]. HHV 8 is also known as Kaposi sarcoma–associated 
herpesvirus because development of Kaposi sarcoma is driven by this virus. The 
seroprevalence of HHV 8 exhibits geographic variation; it is most common in the 
Mediterranean, Middle East, and some areas of Africa. 
Clinical Manifestations 
Transplant recipients with HHV 6 infection commonly have fever, bone marrow 
suppression, interstitial pneumonitis, and/or encephalitis. In addition, hepatitis and 
cutaneous rash have also been found in patients infected with HHV 6. Severe cases may 
progress to aplastic bone marrow and secondary infection with fungal and/or other viral 
pathogens. Symptoms associated with HHV 7 are not as well documented. Patients with 
HHV 8 may have cutaneous lesions, fever, and evidence of bone marrow suppression. 
Diagnosis and Monitoring 
Patients who are HHV 6–negative before transplantation appear to have a higher incidence 
of infection, although most cases are reactivations because more than 90% of patients are 
seropositive by adulthood. As with other viral illnesses, quantitative PCR is useful in 
diagnosis and in monitoring patients with this infection. HHV 8 serostatus of the donor and 
recipient may be assessed on the basis of geographic location. Patients who are seropositive 
before transplantation, who are at risk for primary infection, or who have Kaposi sarcoma 
can then be monitored after transplantation by means of HHV 8 viral loads [79]. 
Prevention and Treatment 
Routine prophylaxis for HHV is not recommended [79]. Symptomatic patients may be 
treated with ganciclovir, foscarnet, or cidofovir, in combination with immunosuppression 
reduction [79]. For patients with Kaposi sarcoma, reduction and/or withdrawal of 
immunosuppression is first-line therapy, and conversion from calcineurin inhibitor therapy 
to sirolimus is also recommended due to regression of KS lesions after conversion [79]. 
Surgery, irradiation, and chemotherapy may be required in patients who do not respond to 
the reduction in immunosuppression.  
2.3.5. Epstein Barr virus 
EBV is a herpesvirus that infects most people at a young age and causes infectious 
mononucleosis. In immunocompromised patients, primary EBV infection or reactivation of 
latent infection can cause PTLD, a feared consequence of immunosuppressive therapy. Risk 
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factors for the development of early PTLD include EBV seronegativity at the time of 
transplantation (leaving children at higher risk than adults), type of organ transplanted, 
type and degree of immunosuppression, CMV donor/recipient mismatch, CMV disease, and 
lymphocyte depleting antibody induction, while late PTLD may be related to duration of 
immunosuppression, type of organ transplanted, and older age of the recipient [80]. Kidney 
transplant recipients are considered low risk for development of PTLD (~1%). PTLD affects 
the transplant allograft in approximately 30% of cases. Lesions in the central nervous system 
are the most difficult to treat. In general, early occurrence of PTLD is polyclonal and easier 
to treat, whereas late PTLD is often monoclonal, and infected B cells may lose CD20 
expression, making treatment difficult. 
Clinical Manifestations 
Signs and symptoms of PTLD may include those of a primary EBV infection/infectious 
mononucleosis, specifically fever, malaise, and swollen lymph nodes in the neck, tonsils, 
axilla, and/or groin. In addition, patients may have other nonspecific symptoms, depending 
on the type of organ transplanted. 
Diagnosis and Monitoring 
Diagnosis of PTLD is a combination of clinical assessment, blood tests, EBV-related blood 
tests, radiographic imaging, histology, and other adjunctive tests [80]. Pathological 
examination of tissue is the gold standard for the diagnosis of PTLD; excisional biopsies are 
preferred over needle biopsies. No specific staging system exists for PTLD; however, the 
current recommendation is to use the Ann Arbor staging classification system with 
Cotswold’s modifications, which is used to stage non-Hodgkin lymphoma. Diagnosis is 
based on morphological classification, origin cell type, presence of EBV, and presence of 
CD20+ cells [80, 81]. 
Prevention 
Because no definitive methods to prevent PTLD are known, diligent monitoring of high-risk 
patients is needed; this is done by performing serial EBV PCR. Risk is defined as high in 
D+/R- pairs, children, and patients receiving high dose and/or intensity immunosuppression 
[80, 81]. Utilization of ganciclovir/valganciclovir for CMV prophylaxis may give some 
protection, as ganciclovir has greater in vitro activity against EBV than acyclovir. 
Treatment 
Unfortunately, controlled trials in the treatment of PTLD are generally lacking. Key 
strategies for the management of patients with PTLD include reduction in 
immunosuppression, surgical resection, and local irradiation [80]. Secondary treatments 
may include antivirals, immunoglobulin, and monoclonal antibodies against B cells [80]. 
Anti-CD20 antibody (rituximab) is promising as first-line therapy after immunosuppression 
reduction because of its high specificity for B cells with a low adverse event profile. 
Cytotoxic chemotherapy (such as CHOP) is often used when first- and second-line therapies 
fail. Patients with CNS lesions may be treated with local radiotherapy, intrathecal anti-CD20 
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antibody, and/or interferon α [80]. EBV-specific cytotoxic T lymphocytes (CTL) may also have 
a role in the treatment of PTLD [82]. Patients may receive another transplant after successful 
treatment of PTLD; however, careful examination of patient-specific factors must occur. 
2.3.6. Adenovirus 
A concern mostly in children, adenovirus is a virus with many different serotypes that may 
cause diverse signs and symptoms during acute illness. Adenovirus is transmitted through 
respiratory secretions, fecal-oral route, and fomites; donor transmission has also been 
postulated in several reported cases. Adenovirus infection may occur in transplant 
recipients of any age; however, complications occur more commonly, and infections may be 
more severe in children [83]. 
Clinical Manifestations 
Symptomatic disease can vary greatly, ranging from self-limiting febrile illness, to 
hemorrhagic cystitis or gastroenteritis, to severe infection with necrotizing hepatitis or 
pneumonia. 
Diagnosis and Monitoring 
The gold standard for diagnosis of adenovirus is by culture or antigen detection. In patients 
with invasive disease, tissue specimens can be examined for histology (“smudge cells” 
signaling cytopathic inclusions; the gold standard) or adenovirus PCR may be performed on 
the specimen [83]. 
Prevention and Treatment 
No specific preventative measure is available, other than avoiding the spread of the virus 
via droplet and contact precautions for infected patients [83]. Supportive care, in 
conjunction with a decrease in immunosuppression is the standard of care for these patients. 
The use of antiviral agents such as ribavirin, ganciclovir, cidofovir, and respiratory syncytial 
virus immunoglobulin have been reported [83]. Cidofovir has the best data supporting its 
use, however its nephrotoxicity is an important concern in renal transplant recipients [83].  
2.3.7. Human parvovirus B19 
By adulthood, 30% to 60% of people are seropositive for parvovirus B19, an infection that 
usually is asymptomatic or manifests as a mild illness called erythema infectiosum in 
school-aged children and is commonly acquired through infected respiratory secretions. 
Parvovirus infects erythroid precursor cells, causing areticulocytic anemia in patients with 
severe infection. 
Clinical Manifestations 
Parvovirus infection develops in approximately 1% to 2% of transplant recipients, resulting 
in a pure red cell aplasia with a low or absent reticulocyte count. Other manifestations of the 
infection may include fever, arthralgia, rash, pancytopenia, and hepatitis. 
 Current Concepts in Kidney Transplantation 184 
Diagnosis and Monitoring 
In transplant recipients, parvovirus B19 immunoglobulin M is a marker for ongoing 
infection, and parvovirus B19 DNA PCR may also be useful. Both have limitations, 
however, because transplant recipients may not be able to mount a response, making the 
serologic findings a less than ideal marker, whereas PCR may remain positive for up to 9 
months after the initial infection. Therefore, the best diagnostic tool appears to be a positive 
PCR in a patient with pure red cell aplasia. Bone marrow biopsy may be considered for 
patients with signs and symptoms but negative serology and PCR [84].  
Prevention and Treatment 
No strategies are available to prevent parvovirus B19 infection in transplant recipients, 
although a vaccine is being developed [84]. The treatment of choice for parvovirus B19 
infection is IVIG, although the optimal dosing regimen and duration of therapy are not 
clear. Current guidelines recommend 400 mg/kg/day for 5 days, possibly in conjunction 
with immunosuppression reduction [84]. 
2.3.8. Human papilloma virus 
Patients with human papillomavirus (HPV) infection have an increased risk of cervical 
intraepithelial neoplasia (CIN) and cervical cancer, as well as risk for squamous cell cancers 
(SCC) of the anus, vulva, vagina, and penis [85]. The role of HPV in skin and oropharyngeal 
SCC is less clear [85]. The virus, in combination with exposure to ultraviolet radiation and 
the degree and length of immunosuppression are important factors in the development of 
cutaneous lesions. Viral warts may progress to these cancers in immunocompromised 
patients, with HPV DNA being found in 70% to 90% of cutaneous tissue in patients with 
SCC. Many strains of HPV exist, with HPV 5 and HPV 8 appearing to have a higher 
prevalence in transplant recipients with skin cancers. 
Clinical Manifestations 
Infected patients have cutaneous and anogenital warts (verruca vulgaris). Although less 
common, HPV may also be manifest as a respiratory tract infection.  
Diagnosis and Monitoring 
Diagnosis is made by examination of cutaneous warts during physical examination. Warts 
that look suspicious (eg, discolored) should be sampled by biopsy because of the known risk 
of malignant transformation of these lesions. In addition, suspicious anogenital warts 
should also be sampled, particularly as these lesions may be clinically indistinguishable 
from squamous epithelial lesions. Renal transplant candidates and recipients should have a 
pap smear yearly due to the increased risk of cervical cancer in this population [85]. HPV 
viral load by PCR is also utilized on clinical specimens.  
Prevention 
Patients with preexisting lesions should receive treatment before transplantation. An HPV 
vaccine has been developed, although its role prior to transplantation remains to be 
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determined. Currently, it is recommended for use pre-transplant in the FDA-approved 
patient populations [85]. After transplantation, high-risk patients (those with a history of 
warts, keratoses, skin cancer, or long-term immunosuppression) should be followed up by a 
dermatologist every 3 to 6 months. Patients must be educated to avoid excessive sun 
exposure, to wear protective clothing when in the sun, and to use sunscreen to protect them. 
For those patients (or their partners) with anogenital lesions, sexual transmission should be 
avoided by abstinence or condoms (although condoms do not provide complete protection). 
Treatment 
It is recommended that warts causing physical and/or psychological signs or symptoms be 
treated with cytotoxic agents that destroy the infected epidermis, such as salicylic acid, lactic 
acid, or cryotherapy. In addition, surgical removal and physical ablation are often 
employed; a more rare treatment includes stimulation of the local immune response in the 
infected area [85]. 
2.3.9. Polyomavirus 
Polyomavirus nephropathy (PVN) is a significant cause of morbidity and graft loss in renal 
transplant recipients, and is described in great detail in another chapter of this textbook.  
2.3.10. Hepatitis B 
Chronic hepatitis B virus (HBV) infection was traditionally considered a risk factor for 
poorer patient and graft survival after kidney transplantation [86]. In the more recent era, 
which is distinguished by the availability of oral anti-viral agents, analysis of OPTN/UNOS 
data has shown equivalent patient and graft survival in HBV(+) versus HBV(-) kidney 
transplant recipients [87]. The risk of liver failure does, however, continue to be increased in 
HBV(+) patients [87].  
Diagnosis and Monitoring 
HBV(+) patients on anti-viral therapy should be monitored every three months after 
transplantation, specifically for viral load (HBV DNA) and ALT, both to monitor efficacy as 
well as assess for development of resistance [88]. In addition, those with cirrhosis should be 
monitored yearly for development of hepatocellular carcinoma (HCC) via hepatic 
ultrasound and alpha fetoprotein [88].  
Prevention and Treatment 
All patients should be vaccinated against HBV, preferably before beginning dialysis due to 
poorer immune response to the vaccine in dialysis and transplant patients [89]. Re-
vaccination should occur when hepatitis B surface antibody titers fall below 10 mIU/mL [88]. 
Utilization of nucleoside or nucleotide analogues to suppress HBV viral load in HBV-
infected kidney transplant recipients has led to reduction in mortality, although 
development of hepatocellular carcinoma still exists and requires routine monitoring [90]. 
All HBV surface antigen positive transplant recipients should receive prophylaxis with 
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tenofovir, entecavir, or lamivudine, although concerns over lamivudine resistance limit its 
use [88]. Use of interferon therapy after transplant is not recommended due to risk of 
precipitating rejection [88].  
2.3.11. Hepatitis C 
Hepatitis C is the leading indication for liver transplantation in the United States, and up to 
38% of kidney transplant recipients worldwide have hepatitis C infection [91]. Hepatitis C 
infection is associated with poorer patient and graft survival after kidney transplantation as 
compared to Hepatitis C(-) patients, however, outcome after transplant is better than 
remaining on dialysis [92]. As with hepatitis B, it is important to clear the virus or decrease 
viral load before transplantation due to risk of rejection with post-transplant interferon.  
Monitoring 
After transplant, the ALT of HCV(+) patients should be monitored monthly for 6 months, 
and then every 3 to 6 months thereafter [88].  
Treatment 
Use of interferon therapy after kidney transplantation is not recommended due to risk of 
precipitating rejection, and should be used only when benefit clearly outweighs the risk of 
rejection [88]. This may include patients with fibrosing cholestatic hepatitis or life-
threatening vasculitis. The use of newer oral agents for hepatitis C (including telaprevir and 
boceprevir) is contraindicated in transplant recipients due to lack of research studies [93]. 
Pharmacokinetic studies conducted in healthy volunteers have demonstrated significant 
drug interactions between telaprevir and cyclosporine or tacrolimus, which could lead to 
life-threatening toxicity [93, 94].  
2.3.12. Less common but significant viral infections after transplantation 
Novel Influenza A (H1N1) is a swine-origin influenza A virus that became a pandemic in 
2009. In kidney transplant recipients, H1N1 caused significant morbidity and mortality [95-
98], and mortality is higher in transplant recipients compared to the general population [97]. 
More severe cases develop pneumonia and may require ICU admission and ventilator 
support. Poorer outcomes are associated with delayed introduction of treatment; oseltamivir 
has been used to successfully treat transplant recipients with H1N1 [96-98].  
West Nile Virus (WNV) is a single-stranded RNA virus of the Flaviviridae family that is 
transmitted to humans by mosquitoes. Since 1999, an increasing number of cases have 
occurred in North America. A limited number of severe cases have been reported in solid-
organ transplant recipients, causing morbidity and mortality. Compared with the general 
population, where the infection rate for WNV was 5 per 100,000, the rate in transplant 
recipients was 200 per 100,000 (P < .001) [99]. A seroprevalence study found a 0.25% 
seroprevalence and a resultant 40% risk of meningoencephalitis in a transplant patient with 
community acquired WNV [100]. Similar studies of immunocompetent persons estimate the 
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risk of meningoencephalitis to be less than 1%. Transmission through infected blood 
transfusion and/or transplanted organ is a risk [101]. Clinical signs and symptoms of 
infection in transplant recipients included fever, confusion, headache, weakness, 
encephalitis, and meningitis [99].  
Based on the limited number of cases of WNV infection in transplant recipients, it appears 
that delayed seroconversion due to immunosuppression may occur, leading to delayed 
diagnosis. Other diagnostic methods such as PCR may be used, although that method is not 
useful in all patients [99]. Transplant recipients should be educated about the risks of WNV 
infection, particularly in endemic areas. Patients should be encouraged to use insect repellant 
and to avoid the outdoors during the periods of dawn and dusk, when mosquitoes are most 
active. Treatment of WMV in recipients of solid-organ transplants has generally been empiric 
and supportive. Both interferon and ribavirin have in vitro activity against WNV, but available 
data are not sufficient to associate use of these agents with clinical outcome. In addition, IVIG 
may be useful. Reduction or discontinuation of immunosuppression, based on the clinical 
situation, is most likely important adjunct treatment. 
Lymphocytic choriomeningitis virus (LCMV) is a rodent-borne, Old World arenavirus. 
Four clusters of LCMV infection in solid-organ transplant recipients have been reported, with 
some cases specifically linked to donor transmission of the virus [102, 103]. Liver function and 
coagulation abnormalities, transplant organ dysfunction, fever, rash, diarrhea, hyponatremia, 
thrombocytopenia, hypoxia, and renal failure are manifestations of the infection that develop 
in transplant recipients of infected organs. The mortality rate is high. LCMV is very rare; no 
routine screening is performed on organ donors. LCMV antibodies, immunohistochemistry, 
PCR, and viral culture may be used for diagnosis in suspected cases [102]. Treatment with IV 
ribavirin, in combination with reduction in immunosuppression, may have been beneficial in 
the 1 surviving patient of the outbreak described in reference [102].  
2.3.13. Vaccination in solid-organ transplant candidates and recipients 
Because of the likelihood of poor response to vaccines after transplantation due to inability 
to mount an optimal effective response, it is very important to have all vaccinations up to 
date before transplantation, and to carefully consider timing of administration in the post-
transplant period [104]. Influenza (inactivated) and pneumococcal vaccines should be given 
at their recommended schedules after transplantation, in order to confer as much protection 
to the patient as possible [105]. Household contacts of transplant patients should also 
receive the inactivated influenza vaccine on an annual basis. Live vaccines should be 
avoided in transplant recipients, however their household contacts may receive live vaccines 
if necessary, with the exception of smallpox and oral-poliovirus vaccines [105]. More details 
about vaccination can be found in other chapters within this book. 
2.4. Parasitic infection 
Reactivation of latent parasitic infection in previously infected patients or de novo infection 
by natural means or through the donated organs is of increasing concern in the transplant 
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community. Multiple factors are contributing to increased incidence, including the presence 
of transplant centers in endemic areas, donor and/or recipient travel from endemic areas to 
Western countries for transplant, transplant tourism, immigrants with latent infection, 
leisure travel by recipients, and use of non-cyclosporine based immune regimens [106]. 
Parasitic diseases affecting transplant recipients are outlined in Table 1. 
Classification Parasitic Infection 



























Donors from indiginous areas 
should be tested 
Leishmania 
(Old World and New 
World) 










Identification of species 




Fever, malaise, hemolytic 
anemia, possible adult 
respiratory distress 
syndrome
May be difficult to distinguish 
babesiosis from malaria; 
morphology and DNA testing 





cutaneous lesions, sinusitis, 
disseminated disease
Biopsy diagnosis of cutaneous 
lesions and cerebrospinal fluid 











Difficult to eradicate; reduction 
in immunosuppression may be 
important in clearing infection. 
Reduce risk by drinking only 
municipal or bottled water 
Entamoeba histolytica
Amebic colitis, liver 
abscess; less commonly 
pulmonary, cardiac, brain 
involvement
Reduce risk by drinking only 







(Gram negative GI 
organisms), acute, severe 
abdominal disease, 
eosinophilia
Difficult to eradicate; high 
mortality with disseminated 
infection 
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Classification Parasitic Infection 






Abdominal pain, anorexia, 
diarrhea; hematuria, 
dysuria, urinary frequency; 
fibrosis of liver or bladder 
and ureters 
Reduce risk by avoiding fresh 




Liver failure; possible 
extrahepatic involvement in 
lungs, brain 
May be difficult to distinguish 
from hepatic malignancy 
Table 1. Parasitic diseases affecting transplant recipients 
2.5. Drug-drug interactions and toxicities of anti-infective agents 
There are a number of clinically significant drug interactions and toxicities that must be 
considered when treating infection in the transplant population (see Table 2). Drug levels of 
several of the primary immunosuppressants must therefore be monitored frequently and 
dose adjustment is needed to achieve the desired level of the immunosuppressant [107]. 




Drug Interactions or Important Toxicities 




Increase levels of cyclosporine, tacrolimus, 
sirolimus and everolimus via Cytochrome 
P450 3A4 inhibition 
Empiric dose adjustment of 
immunosuppressant is 
recommended when 
initiating azole therapy 
Clotrimazole 
(topical) [108, 109]
Increase levels of tacrolimus (and possibly 
others) via Cytochrome P450 3A4 inhibition 
in the gut 
Dose adjustment often 
necessary 
Amphotericin B Enhanced nephrotoxicity 
When therapy needed for 
invasive fungal infection, 
liposomal formulations 
preferred to reduce risk of 
nephrotoxicity 
Aminoglycosides Enhanced nephrotoxicity Avoid when possible 
Macrolide 
antibiotics 
Increase levels of cyclosporine, tacrolimus, 
sirolimus and everolimus via Cytochrome 
P450 3A4 inhibition 
Effect most pronounced with erythromycin 
and clarithromycin; more rare with 
azithromycin 
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Anti-Infective 
Agent/Class 
Drug Interactions or Important Toxicities 
in the Transplant Population 
Additional Information 
Rifamycins 
Decrease levels of cyclosporine, tacrolimus, 
sirolimus and everolimus via Cytochrome 
P450 3A4 induction 
Empiric dose adjustment of 
immunosuppressant is 
recommended when 
initiating rifamycin therapy 
Ganciclovir, 
Valganciclovir 
Enhanced bone marrow suppression 




Enhanced nephrotoxicity Avoid when possible 
Table 2. Important Drug Interactions and Toxicities with Anti-Infective Agents and 
Immunosuppressants 
3. Malignancy 
The net state of immunosuppression also affects the development of post-transplant 
malignancy. This includes not only de novo malignancy, but also recurrence of pre-transplant 
lesions. As seen in Table 3, a significant number of cancers are related to oncogenic viral 
infections. The Transplant Cancer Match Study assessed cancer risk in more than 175,000 
solid organ transplant recipients, as compared to the general population [97]. It is important 
to note that this analysis includes only patients transplanted in the U.S., and the importance 
of biliary tract and bladder cancers due to parasitic infection outside of the U.S. are not 
represented in the analysis. In addition, non-melanoma skin cancers are not included in the 
analysis. Overall, transplant recipients had a cancer risk twice that of the general 
population. For kidney transplant recipients, the standardized incidence ratio for the most 
common malignancies seen across all transplant recipients regardless of organ was highest 
for kidney cancer (6.66), non-Hodgkin lymphoma (6.05) and lung cancer (1.46).  
Non-melanoma skin cancers are the most common malignancy seen in the organ transplant 
population, and the incidence of these cancers is 3 to 5 times that of the general population. 
Although both basal (BCC) and squamous cell carcinoma (SCC) occur, SCC tends to occur 
more frequently in transplant recipients, as compared to a predominance of BCC in the 
general population. Both SCC and BCC occur at a younger age when compared to the 
general population. In addition, SCC tends to be more aggressive in transplant recipients as 
compared to the course in the general population [110]. This includes an increased number 
of primary tumors, deep tissue spread, perineural and lymphatic invasion, recurrence, and 
need for radiation or chemotherapy [110]. Guidelines for the management of transplant 
patients with SCC were published in 2004 [111]. Recurrent, de novo and donor-transmitted 
melanoma are also a concern in transplant recipients [112]. Guidelines for proposed 
reduction in immunosuppression for transplant patients with skin cancers are available 
[113].  
Renal cell carcinoma (RCC) of the native kidney(s) is diagnosed in 0.3% to 4.8% of kidney 
transplant recipients [114, 115], and in the transplant kidney in approximately 0.2% [116]. 
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Patients with pre-transplant cystic lesions are more likely to develop RCC by three years 
after transplant compared to those without (2.3% vs. 0.7%, respectively) [115]. Risk factors 
for developing RCC after transplant have included pre-transplant cystic disease/lesions, 
male gender, African-American race, older recipients (> 65 years at transplant), longer time 
on dialysis prior to transplant, older donor age (> 55 years), and treatment of acute rejection 
within 1 year of transplant [114, 115]. Most cases of RCC have papillary or clear cell 
histology, and RCC in one kidney is associated with RCC in the contralateral native kidney. 
Most cases are diagnosed incidentally, are low-grade, and are managed by native 
nephrectomy. More aggressive tumors may require chemotherapy, minimization or change 
in immunosuppression, and/or radiation. Interestingly, the mTOR inhibitor everolimus is 
FDA-approved as second line therapy for advanced RCC, and thus may be a preferred 
immunosuppressant in this setting.  
Historically, post-transplant lymphoproliferative disorder (PTLD) has been a major concern 
for solid organ transplant recipients. A recent analysis of Scientific Registry of Transplant 
Recipients (SRTR) data for 156,740 kidney transplant recipients found an incidence of 0.7% 
at 5 years and 1.4% at 10 years [117]. This analysis, similar to prior reports, showed a clear 
distinction between early (less than 2 years after transplant) and late-onset (more than 2 
years) PTLD. Risk factors for early PTLD on multivariate analysis include age 19 or younger 
at transplant, non-Hispanic white ethnicity, EBV negative serostatus at transplant, and CMV 
negative serostatus at transplant, while risk factors for late PTLD include age 19 or younger 
or 50 years or older at transplant and non-Hispanic white ethnicity. The use of induction 
therapy, including when the analysis was limited to T cell depleting agents, did not increase 
the risk of PTLD. In addition to PTLD, elderly transplant recipients are at increased risk for 
various hematologic malignancies [118]. Treatment of PTLD may include reduction in 
immunosuppression, surgery, anti-viral therapy, chemotherapy (including 
immunochemotherapy (rituximab)), and/or radiation.  
 
Infectious Agent Associated Sites/Types of Cancer 
Epstein Barr Virus (EBV) 
Non-Hodgkin Lymphoma, Hodgkin Lymphoma, 
PTLD, Nasopharyngeal 
Human Papillomavirus Cervix, Vulva, Vagina, Penis, Anus, Oropharynx 
Hepatitis B and Hepatitis C Liver 
Human Herpesvirus 8 (HHV8) Kaposi sarcoma 
Helicobacter pylori Stomach 
Table 3. Oncogenic Infectious Agents 
4. Conclusion 
In summary, complications of over-immunosuppression after solid-organ transplantation 
can lead to significant morbidity and mortality if not promptly diagnosed and treated. 
However, the growing armamentarium of knowledge, diagnostic tools and therapeutic 
agents available for the prevention and treatment of these infections and malignancies will 
continue to improve the quality of care for these patients. 
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